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Abstract
Background The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with 
COVID-19. We present relationships of age, sex, and nationality to presenting symptoms.
Methods International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-con-
firmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to 
evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms.
Results ‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 
92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds 
(respectively 80, 79, 69%; at least one 95%). They were reported less frequently in children (≤ 18 years: 69, 48, 23; 85%), 
older adults (≥ 70 years: 61, 62, 65; 90%), and women (66, 66, 64; 90%; vs. men 71, 70, 67; 93%, each P < 0.001). The most 
common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was 
confusion. Regression models showed significant differences in symptoms with sex, age and country.
Interpretation This international collaboration has allowed us to report reliable symptom data from the largest cohort of 
patients admitted to hospital with COVID-19. Adults over 60 and children admitted to hospital with COVID-19 are less 
likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confu-
sion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical 
symptoms than men.
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Background
Despite the pandemic’s immense human cost, enormous 
economic toll, and extensive research response, the precise 
clinical characteristics of COVID-19 remain unclear [1]. At 
the start of the outbreak, COVID-19 was broadly charac-
terised as a severe respiratory illness presenting with fever, 
cough and an atypical pneumonia [2–5]. Altered sense of 
taste and smell have since been found to be strongly associ-
ated with the disease [6, 7]. However, a review of 77 obser-
vational studies found substantial proportions of patients 
presenting with less typical symptoms [8].
Different sets of clinical criteria for suspected COVID-
19 have been produced by the World Health Organization 
(WHO) [9], Centers for Disease Control and Prevention in 
the United States [10], Public Health England [11], and the 
European Centre for Disease Prevention and Control [12] 
(Table 1). Defining presenting symptoms of COVID-19 is 
further complicated by clinical experience suggesting that 
patients frequently present with atypical symptoms other 
than cough, fever and shortness of breath. This variation in 
the clinical characterisation of COVID-19 is problematic, as 
case definitions are used to guide clinical diagnosis, disease 
surveillance, and public health interventions.
The International Severe Acute Respiratory and Emerg-
ing Infection Consortium (ISARIC) cohort study is an 
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international collaboration to gather reliable observational 
data about patients admitted to hospital with COVID-19 
[13]. Here, we present an analysis of how symptoms of 
patients admitted to hospital with confirmed COVID-19 vary 
by age and sex. Secondarily, we investigated how sensitivity 
of clinical case definitions varied among these populations, 
and explored heterogeneity among countries.
Methods
Study design and setting
This analysis used international observational data of clini-
cal features of patients admitted to hospital with COVID-
19 between 30 January and 3 August 2020. The ISARIC/
WHO Clinical Characterisation Protocol for Severe Emerg-
ing Infections is a standardized protocol for investigation of 
severe acute infections by pathogens of public health inter-
est [14]. ISARIC case report forms [15] allow standard-
ized data collection from the start of an outbreak and rapid 
dissemination of clinical information [3, 16–20]. Different 
tiers of data collection exist to allow sites to collect data 
to the highest possible standards while recognising vary-
ing levels of resource for data collection during epidemics. 
Details of symptoms at admission were included on the case 
report forms for all tiers. Data were collected via electronic 
‘Core’ and ‘Rapid’ forms, and through aligned forms by 
ISARIC-4C Coronavirus Clinical Characterisation Consor-
tium in the United Kingdom [21] and the COVID-19 Critical 
Care Consortium [22]. Investigators from 41 countries are 
using Research Electronic Data Capture (REDCap, version 
Table 1  Clinical case 
descriptions in use
Source Symptoms
World Health Organization [9] A combination of acute fever and cough or 
A combination of three or more of:
 Fever
 Cough
 General weakness and fatigue
 Headache
 Myalgia
 Sore Throat
 Coryza
 Dyspnoea
 Anorexia
 Nausea and vomiting
 Diarrhoea
 Altered mental status
Centers for Disease Control, United States [10] At least two of:
 Fever
 Chills
 Rigors
 Myalgia
 Headache
 Sore throat
 New olfactory and taste disorder or 
At least one of:
 Cough
 Shortness of breath
 Difficulty breathing
Public Health England [11] New cough, or temperature ≥ 37.8 °C, or a 
loss or change in sense of smell or taste
European Centre for Disease Prevention and Control [12] At least one of
 Cough
 Fever
 Shortness of breath
 Sudden onset anosmia, ageusia or dys-
geusia
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8.11.11, Vanderbilt University, Nashville, Tenn.) to contrib-
ute their data to a central database hosted by the University 
of Oxford. Additional data were submitted by investigators 
from Malaysia, Russia [23] and Spain, who had used alterna-
tive data collection forms and databases. This observational 
study required no change to clinical management and per-
mitted enrolment in other research. The study was approved 
by the World Health Organization Ethics Review Committee 
(RPC571 and RPC572). Local ethics approval was obtained 
for each participating country and site according to local 
requirements. All investigators retained full rights to their 
data.
Study population
Patients of any age admitted to hospital with suspected or 
confirmed COVID-19 were eligible for recruitment. Some 
versions of the case report form included specific criteria 
such as fever and cough, but investigators were able to 
include patients with a clinical suspicion of COVID-19 even 
if these criteria were not met. This analysis was limited to 
patients who were admitted to hospital with symptomatic 
laboratory-confirmed COVID-19: laboratory confirmation 
was classified according to sites’ local diagnostic methods. 
We excluded asymptomatic patients who had been admitted 
to hospital for isolation and patients admitted for other con-
ditions who subsequently developed COVID-19 symptoms.
Variables and measurement
Variables used in this analysis were age, sex at birth, symp-
toms, date of symptom onset, SARS-CoV-2 confirmation, 
and country of recruitment. To allow proportions to be cal-
culated with a reliable denominator, only symptoms speci-
fied on the case report forms [15, 21, 22] were included in 
this analysis. The list of symptoms collected is presented 
with the results.
Statistical methods
Data were converted to Study Data Tabulation Model (ver-
sion 1.7, Clinical Data Interchange Standards Consortium, 
Austin, Tex.) to allow inclusion of data submitted not using 
the ISARIC case report forms. We excluded patients with all 
symptoms recorded as missing or unknown, and those with 
missing age, sex or country.
Continuous variables were expressed as median with inter-
quartile range (IQR), and categorical variables as counts with 
percentages. We tested for differences between female and 
male patients using Wilcoxon rank-sum tests for continuous 
variables and chi-square tests for categorical variables. We 
grouped patients into ten-year age bands (with a single group 
for age ≥ 90 years). We plotted the most frequently reported 
symptoms by age group, presenting missing data as a third 
category. We collated symptoms according to four sets of clini-
cal criteria. These were based on published criteria [9–12] 
but modified to omit symptoms with large numbers of miss-
ing data due to being added to the case report form part way 
through the data collection period (altered sense of taste and 
smell) or not being collected in all datasets (anorexia):
1. Fever plus cough; or any three of fever, cough, fatigue, 
headache, myalgia, sore throat, rhinorrhoea, shortness of 
breath, nausea and vomiting, diarrhoea, and confusion;
2. Cough or shortness of breath; or any two of fever, myal-
gia, headache, and sore throat;
3. Cough or fever;
4. At least one of cough, fever, and shortness of breath.
Patients with missing details of cough, fever or shortness 
of breath were omitted from the composite groups; patients 
missing details of symptoms included in the lists of criteria 
1 and 2 were included, and were classified according to the 
non-missing symptoms. We plotted proportions of patients 
meeting each set of criteria by ten-year age group, with 95% 
confidence intervals (CI) calculated using the Clopper–Pear-
son method.
We used logistic regression to identify associations of 
age and sex with the twelve most prevalent symptoms. Age 
group and sex were included as fixed effects, with country 
as a random intercept. To display heterogeneity between 
countries on the same scale as the fixed effects, we calcu-
lated median odds ratios (MOR) [24]. This quantifies vari-
ation between countries by comparing odds of an outcome 
between randomly chosen persons in different clusters who 
share the same covariates [24]. MORs are defined as a com-
parison of the group with greater propensity to the group 
with lower propensity, so lie in the range 1 to infinity [24]. 
We plotted the MOR to show the magnitude of the effect of 
heterogeneity and allow comparison with the fixed effects 
in our data.
79% of patients were recruited in a single country (United 
Kingdom). As a sensitivity analysis, we repeated the analysis 
excluding patients from this country to see if results substan-
tially changed. Finally, we plotted age-stratified symptom 
frequencies for each country with at least 250 patients.
No minimum sample size was calculated. All significance 
tests were two-tailed. Analyses were performed using R (ver-
sion 3.6.2, R Foundation for Statistical Computing, Vienna, 
Austria) with packages including binom, Epi, ggplot2, lme4, 
sjstats, tableone, and tidyverse.
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Results
Data were available for 99 623 patients. We excluded 24 336 
who did not have documented SARS-CoV-2 confirmation, 
3290 with missing data, and 5794 who developed COVID-
19 after admission to hospital. 6094 patients were admit-
ted to hospital with asymptomatic COVID-19, with the 
greatest proportion in the age band 10–20 years (46% of 
patients admitted in that age group). The greatest propor-
tion of asymptomatic patients was in Malaysia (49%), where 
hospitalization was compulsory throughout the data collec-
tion period for people with COVID-19. We included 60 109 
patients in the analysis (Fig. 1), recruited from 394 sites in 
43 countries (Supplementary Table 1), in this analysis. The 
median age of included patients was 70 years (IQR 54–82; 
Table 2). 929 (1.5%) were 18 years old or younger. Age 
distribution of patients varied among countries, between a 
median of 10 years in Poland, and 73 years in the United 
Kingdom (Supplementary Figure 1). 34 641 (58%) patients 
were male.
The most frequently reported symptoms were fever, 
cough and shortness of breath (Table 3). These symptoms 
were each more prevalent in male patients, whereas less 
typical symptoms such as confusion, nausea and vomiting, 
diarrhoea, chest pain, headache and abdominal pain were 
more prevalent in female patients. The greatest sex-related 
difference was for nausea and vomiting, reported by 23% 
of female patients but only 16% of male patients. For most 
symptoms, the greatest prevalence was reported in adults 
aged between 30 and 60 years, decreasing toward extrem-
ities of age (Fig. 2). Frequency of confusion increased 
with age. Large numbers of patients had missing data for 
anorexia, severe dehydration, altered sense of taste and 
smell, and inability to walk, as these were not included 
on all case report forms. Altered sense of taste and smell, 
which we had excluded from the composite criteria, were 
experienced by only 7.4 and 6.2% respectively of patients 
with non-missing data. 
Data on cough, fever or shortness of breath were miss-
ing for 3446 patients. The composite clinical criteria 
were calculated for the remaining 56 663 patients. Each 
set of criteria was met by a greater proportion of patients 
aged 30–60 years than those toward either extreme of age 
(Fig. 3). The criteria based on WHO’s clinical criteria [9] 
(fever plus cough; or any three of fever, cough, fatigue, 
headache, myalgia, sore throat, rhinorrhoea, shortness of 
breath, nausea and vomiting, diarrhoea, and confusion) 
were met by 40 911 (72%) patients, but only 51% of those 
aged 18 years and under, and 67% of those aged 70 years 
Fig. 1  Flow of participants in this analysis. ISARIC Core and 
ISARIC Rapid represent data collected internationally via two sets 
of case report forms; ISARIC 4C and COVID-19 CCC data were 
collected on separate databases using aligned case report forms; 
Non-REDCap data were submitted from additional sites and were 
collected with different case report forms. 4C, Coronavirus Clini-
cal Characterisation Consortium; CCC, Critical Care Consortium; 
ISARIC, International Severe Acute Respiratory and emerging 
Infection Consortium; REDCap, Research Electronic Data Capture; 
SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
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or over. The most sensitive criteria were at least one of 
cough, fever and shortness of breath, met by 52 041 (92%) 
participants. These criteria were met by 85% aged 18 years 
and under, and 90% of those aged 70 years or over. Each 
set of criteria were met by a greater proportion of male 
than female patients (Table 3).
For the 4622 patients whose symptoms did not meet any 
assessed case definitions, the most frequent symptom was 
confusion (47%; Table 4). This increased with age to 66% 
of those aged 90 years or older. Nausea and vomiting, and 
abdominal pain were the most common symptoms for peo-
ple less than 60 years old who had not met any of the case 
definitions.
In the logistic regression models (Fig. 4 and 5), simi-
lar associations between age and symptoms were seen after 
adjustment for sex as in the unadjusted bar charts. Confusion 
increased with age. Nausea and vomiting, headache, abdomi-
nal pain, and sore throat were each more frequent in younger 
age groups, decreasing with age. Male patients had greater 
odds of fever, cough and shortness of breath, and lower odds of 
gastrointestinal symptoms of nausea and vomiting, diarrhoea, 
abdominal pain, chest pain, headache and sore throat. How-
ever, in each case except diarrhoea, the magnitude of the differ-
ence according to sex was much less than the effect of age. The 
MOR for heterogeneity between countries was greater than the 
relationship with sex in all symptoms (Fig. 4). It was of similar 
magnitude to the relationship with age for most symptoms. 
For each symptom, heterogeneity between countries was of a 
similar magnitude to the effect of age, and a greater magnitude 
than sex. 
47 280 (79%) patients were included from the United King-
dom. Excluding these patients, the patterns of symptoms were 
similar to the main analysis (Supplementary Figure 2). The 
peak prevalence of fever, cough and shortness of breath was in 
70- to 80-year olds, and fatigue increased with age. Below the 
age of 50 years, the clinical case definitions tended to be less 
sensitive in the analysis excluding the United Kingdom than in 
the analysis including it; above the age of 70 years each tended 
to be more sensitive (grey lines in Fig. 3). Within countries, 
the baseline prevalence of each symptom varied but patterns 
within countries were broadly similar to the overall results 
(Supplementary Figures 3–14).
Table 2  Patient demographics
IQR interquartile range
a Data are number (percent within columns) unless specified otherwise
b According to World Bank classification [25]
Variablea Overall n = 60 109 Sex
Female n = 25 468 Male n = 34 641 P value
Age (years): median [IQR] 70 [54, 82] 72 [55, 83] 68 [54, 80]  < 0.001
Age bands (years)  < 0.001
 0–10 514 (0.9) 221 (0.9) 293 (0.8)
 10–20 522 (0.9) 221 (0.9) 301 (0.9)
 20–30 1972 (3.3) 872 (3.4) 1100 (3.2)
 30–40 3209 (5.3) 1450 (5.7) 1759 (5.1)
 40–50 5013 (8.3) 1966 (7.7) 3047 (8.8)
 50–60 8581 (14.3) 3280 (12.9) 5301 (15.3)
 60–70 9874 (16.4) 3701 (14.5) 6173 (17.8)
 70–80 12,333 (20.5) 4916 (19.3) 7417 (21.4)
 80–90 13,483 (22.4) 6196 (24.3) 7287 (21.0)
 ≥90 4608 (7.7) 2645 (10.4) 1963 (5.7)
Region  < 0.001
 East Asia and Pacific 3252 (5.4) 1117 (4.4) 2135 (6.2)
 Europe and Central Asia 55,401 (92.2) 23,749 (93.3) 31,652 (91.4)
 Latin America and Caribbean 162 (0.3) 67 (0.3) 95 (0.3)
 Middle East and North Africa 91 (0.2) 35 (0.1) 56 (0.2)
 North America 926 (1.5) 413 (1.6) 513 (1.5)
 South Asia 267 (0.4) 83 (0.3) 184 (0.5)
 Sub-Saharan Africa 10 (0.0) 4 (0.0) 6 (0.0)
Country income  classificationb  < 0.001
 High income 54,836 (91.2) 23,420 (92.0) 31,416 (90.7)
 Upper middle income 5003 (8.3) 1964 (7.7) 3039 (8.8)
 Lower middle or low income 270 (0.4) 84 (0.3) 185 (0.5)
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Discussion
The ISARIC prospective multinational cohort study is the 
largest cohort of patients admitted to hospital with COVID-
19 to date. In this report, we confirmed a relationship 
between patients’ symptoms and their age and sex. The ‘typ-
ical’ COVID-19 symptoms occur most frequently in adults 
aged 30–60 years. Commonly used case definitions can miss 
up to half of children and a third of adults over 70 years who 
are admitted to hospital with COVID-19.
Our results support the findings of smaller cohort stud-
ies that atypical symptoms are more common in older 
adults [26], and correlate with similar findings of atypical 
presentations for pneumonia, bacteraemia and coronary 
Table 3  Symptoms at presentation to hospital with COVID-19
a Data are number (percent of patients with non-missing data within columns) unless specified otherwise
b Number (percent of all patients)
c Patients missing any of cough, fever or shortness of breath are omitted from the composite categories
Variablea Overall, n = 60 109 Sex Missing  datab
Female, n = 25 468 Male, n = 34 641 P value
Fever 41,067 (68.7) 16,649 (65.7) 24,418 (70.8)  < 0.001 291 (0.5)
Cough 40,898 (68.5) 16,683 (65.9) 24,215 (70.4)  < 0.001 401 (0.7)
Shortness of breath 37,577 (65.8) 15,450 (64.0) 22,127 (67.2)  < 0.001 3024 (5.0)
Fatigue 23,319 (46.4) 9889 (46.3) 13,430 (46.5) 0.622 9893 (16.5)
Confusion 13,732 (27.3) 6108 (28.2) 7624 (26.5)  < 0.001 9730 (16.2)
Muscle pains 9472 (20.1) 3952 (19.8) 5520 (20.3) 0.137 12,980 (21.6)
Diarrhoea 10,061 (19.1) 4565 (20.4) 5496 (18.2)  < 0.001 7544 (12.6)
Nausea and vomiting 9891 (18.8) 5099 (22.8) 4792 (15.8)  < 0.001 7464 (12.4)
Anorexia 613 (15.7) 243 (14.3) 370 (16.8) 0.038 56,202 (93.5)
Severe dehydration 3451 (14.8) 1562 (15.4) 1889 (14.3) 0.027 36,756 (61.1)
Chest pain 6953 (13.6) 3084 (14.2) 3869 (13.1) 0.001 8953 (14.9)
Headache 6154 (13.0) 2830 (14.1) 3324 (12.2)  < 0.001 12,796 (21.3)
Sore throat 4880 (10.5) 2135 (10.8) 2745 (10.3) 0.097 13,836 (23.0)
Abdominal pain 5305 (10.4) 2597 (12.0) 2708 (9.2)  < 0.001 9015 (15.0)
Wheeze 3845 (7.9) 1790 (8.6) 2055 (7.4)  < 0.001 11,390 (18.9)
Altered sense of taste 2011 (7.4) 924 (7.8) 1087 (7.1) 0.023 32,830 (54.6)
Joint pains 3229 (7.1) 1459 (7.5) 1770 (6.8) 0.002 14,587 (24.3)
Altered sense of smell 1733 (6.2) 819 (6.7) 914 (5.7) 0.001 31,969 (53.2)
Rhinorrhoea 2382 (5.2) 1041 (5.3) 1341 (5.1) 0.264 14,403 (24.0)
Unable to walk 220 (5.0) 83 (4.4) 137 (5.4) 0.141 55,668 (92.6)
Skin ulcer 978 (2.3) 489 (2.7) 489 (2.1)  < 0.001 18,486 (30.8)
Haemorrhage 993 (2.0) 429 (2.0) 564 (2.0) 0.695 9902 (16.5)
Lower chest wall indrawing 688 (1.6) 235 (1.3) 453 (1.9)  < 0.001 17,887 (29.8)
Seizure 775 (1.6) 352 (1.7) 423 (1.5) 0.169 12,055 (20.1)
Rash 694 (1.4) 287 (1.4) 407 (1.5) 0.555 11,400 (19.0)
Lymphadenopathy 307 (0.7) 147 (0.8) 160 (0.6) 0.099 15,267 (25.4)
Conjunctivitis 251 (0.5) 111 (0.5) 140 (0.5) 0.642 12,491 (20.8)
Ear pain 201 (0.5) 107 (0.6) 94 (0.4) 0.003 19,036 (31.7)
Composite categories 3446 (5.7)c
Fever and cough; or at least three of fever, cough, fatigue, headache, muscle pains, sore throat, rhinorrhoea, shortness of breath, nausea and 
vomiting, diarrhoea, and confusion
40,911 (72.2) 17,014 (71.0) 23,897 (73.1)  < 0.001
Cough or shortness of breath; or at least two of fever, muscle pains, headache, or sore throat
48,464 (85.5) 20,103 (83.9) 28,361 (86.7)  < 0.001
Cough or fever 48,494 (85.6) 19,973 (83.3) 28,521 (87.2)  < 0.001
At least one of cough, fever or shortness of breath
52,041 (91.8) 21,607 (90.2) 30,434 (93.1)  < 0.001
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Fig. 2  Age-specific prevalence of symptoms at hospital admission. Dark blue bars show symptom present, maroon bars show symptom absent, 
pale grey bars show missing data
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artery disease [27, 28]. A lower prevalence of symptoms in 
children and young people has previously been suggested 
[29, 30], but this is the first large international cohort to 
collect data prospectively from both adults and children.
Separate analyses of the ISARIC-4C data have identi-
fied fever, cough and shortness of breath as frequently co-
occurring clusters of symptoms [31, 32]. In children, the 
next most frequent cluster consisted of systemic, enteric and 
Fig. 3  Proportions meeting clinical criteria at hospital admission 
stratified by 10-year age band. Black boxes show the proportion of 
individuals, with error bars showing 95% confidence intervals cal-
culated using the Clopper–Pearson method. The size of each box is 
inversely proportional to the variance, so larger boxes indicate greater 
certainty. Grey boxes with 95% confidence intervals show the pro-
portions in the sensitivity analysis excluding patients recruited in the 
United Kingdom. In panel A, the three symptoms are from the list 
of fever, cough, fatigue, headache, myalgia, sore throat, rhinorrhoea, 
shortness of breath, nausea and vomiting, diarrhoea, and confusion; 
in panel B the two symptoms are from the list fever, myalgia, head-
ache, and sore throat. Patients with missing data for cough, fever or 
shortness of breath are excluded from all four plots
COVID‑19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective…
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mucocutaneous symptoms [31]. For adults, other clusters 
consisted of non-specific viral symptoms, gastrointestinal 
symptoms, upper respiratory symptoms, neurological symp-
toms, and symptoms of bronchospasm [32]. Those data were 
included in this global dataset so the results of these analyses 
are not independent of our results.
We found that differences in symptoms by sex were statis-
tically significant but generally of smaller magnitude. Typi-
cal symptoms of fever, cough and shortness of breath were 
more common in men than in women; all other symptoms 
were equal or more common in female patients. A cohort of 
non-hospitalized patients with COVID-19 in Poland found 
greater differences in symptoms of lack of appetite (55% 
of women, 36% of men) and taste disorder (53% women, 
40% men) [33]. We are unable to determine from our data 
whether these differences reflect differences in health-seek-
ing behaviour between men and women, or physiological 
differences in their response to the infection. Elaboration of 
this difference should be a goal of future research.
Our results suggest considerable heterogeneity among 
countries. We have not attempted to elicit reasons for het-
erogeneity. Potential reasons include cultural idiosyncrasies 
in reporting symptoms, and hospitals’ criteria for admission 
and testing. It might also reflect differences in local patient 
recruitment. Researchers in some countries may be unwill-
ing to recruit confused patients due to requirements for con-
sent, whereas in others, the requirement for consent has been 
waived or could be obtained from a proxy. We explored the 
effect of using the country of recruitment as a random effect 
in regression models and by repeating the analysis excluding 
the largest country. Each analysis suggested an underlying 
pattern of lower frequencies of typical symptoms in children 
and older adults. Therefore, although the prevalence of each 
symptom reported in this study may not apply to all settings, 
we have evidence to support the possibility of age-dependent 
differences internationally.
The size of this cohort is a strength. To our knowledge, 
it is the largest cohort of hospitalized COVID-19 patients 
in the world. However, the study has several limitations. 
First, almost 80% of patients were recruited in a single coun-
try. Moreover, less than 1% of patients were recruited from 
low- or lower–middle-income countries. Second, the cohort 
overwhelmingly includes older adults, with only 1.8% of the 
cohort aged 18 years or younger. Third, our analysis includes 
only patients who were hospitalized with COVID-19 and 
who had a laboratory-confirmed diagnosis. This patient pop-
ulation is more likely to be severely unwell and more likely 
to exhibit symptoms typically associated with COVID-19 
than people who were managed in the community or whose 
disease has not been recognized. Accordingly, the reporting 
of ‘typical’ COVID-19 symptoms in this cohort is likely to 
be an overestimate of the population prevalence. Symptoms 
are subjective and cannot be externally verified. Some differ-
ences for children may reflect that symptoms could only be 
recorded if a caregiver recognised the symptom or the child 
had the appropriate vocabulary to describe it. Similarly, 
some symptoms may be under-reported in elderly patients 
if there are difficulties in communication, for example due 
to delirium. As such, the generalizability of estimates of our 
symptom prevalence is limited. Similarly, there is a shortage 
of studies conducted outside of high-income countries: a 
recent scoping review of clinical characteristics of COVID-
19 identified no large cohorts in non-high-income countries 
except China [8].
The absence of a control group of patients without 
COVID-19 in this dataset prevented estimation of specificity 
or positive and negative predictive values. We are therefore 
prevented from advocating changes to clinical case defini-
tions, as such decisions inevitably require a balance of false-
positive and false-negative rates. However, given the preva-
lence of atypical symptoms in our cohort, we can confidently 
suggest that reliance on clinical case definitions may result 
in missing cases of COVID-19, especially among children 
and older adults. Non-healthcare professionals making deci-
sions regarding isolation may be especially vulnerable to 
missing cases of COVID-19 by adhering to a clinical case 
definition too strictly.
The reported prevalence of COVID-19 may also rely on 
a strict interpretation of case definitions. In settings where 
comprehensive contact tracing is planned, or there is easy 
access to microbiological testing, a highly sensitive case def-
inition is desirable. However, where decisions are based on 
clinical diagnoses, it is important to recognize other patho-
gens that can cause similar constellations of symptoms. The 
addition of symptoms such as confusion or gastrointestinal 
symptoms to the COVID-19 case definition could increase 
sensitivity, but at the cost of reduced specificity. Changes 
in the senses of taste and smell have recently been added to 
case definitions. Our data suggest that these criteria would 
detect only a small proportion of patients admitted to hospi-
tal with COVID-19 who were omitted by other definitions.
These results highlight the need to consider COVID-19 
even if individuals do not display typical symptoms of the 
disease. This is especially the case in children and older 
adults. Given that our results are likely to overestimate the 
sensitivity of the clinical criteria currently used to identify 
patients for testing, our results suggest a lower limit to the 
Fig. 4  Odds of symptoms among patients admitted to hospital with 
COVID-19, stratified by age and sex. Each plot is the result of a logis-
tic regression with a symptom as an outcome. Fixed effects of age in 
ten-year bands (baseline group 50–60  years) and sex are shown in 
black boxes with 95% confidence intervals. The size of each square is 
inversely proportional to the variance of the log odds ratio, so larger 
boxes indicate greater certainty. Clustering by country is included as 
a random intercept and heterogeneity is depicted by circles showing 
the median odds ratio
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proportion of people in the community with COVID-19 
who would not be identified. Addition of confusion as a 
symptom would increase the sensitivity of case definitions 
for older adults; and inclusion of nausea and vomiting or 
abdominal pain would increase sensitivity for children and 
young adults. The high proportion of asymptomatic patients 
identified in patients aged 10–20 years suggests that univer-
sal screening in these ages could be beneficial when there is 
Fig. 5  Age- and sex-specific odds of meeting clinical definitions 
among patients admitted to hospital with COVID-19, stratified by age 
and sex. Each plot is the result of a logistic regression with a compos-
ite group of symptoms as an outcome. Fixed effects of age in ten-year 
bands (baseline group 50–60 years) and sex are shown in black boxes 
with 95% confidence intervals. The size of each square is inversely 
proportional to the variance of the log odds ratio, so larger boxes 
indicate greater certainty. Clustering by country is included as a ran-
dom intercept and heterogeneity is depicted by circles showing the 
median odds ratio. In panel A, the three symptoms are from the list 
of fever, cough, fatigue, headache, myalgia, sore throat, rhinorrhoea, 
shortness of breath, nausea and vomiting, diarrhoea, and confusion; 
in panel B the two symptoms are from the list fever, myalgia, head-
ache, and sore throat. Patients with missing data for cough, fever or 
shortness of breath are excluded from all four plots
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widespread community circulation of COVID-19. Ongoing 
data collection outside high-income countries is needed to 
establish whether alternative case definitions are needed in 
different settings. Work is also ongoing to determine whether 
some constellations of symptoms are associated with better 
or poorer outcomes than others.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s15010- 021- 01599-5.
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